Unity Biotechnology, Inc., a San Francisco, CA-based biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, closed a $55m Series C financing.
Backers included EcoR1 Capital Fund, 6 Dimensions Capital, Altitude Life Science Ventures, Fidelity Management & Research Company, Baillie Gifford, Partner Fund Management, Pivotal Alpha Limited, Invus Opportunities, ARCH Venture Partners, Venrock, Founders Fund and the Longevity Fund.
The company intends to use the funds to advance its lead senolytic drug candidates into human clinical trials.
Led by Keith Leonard, chairman and chief executive officer, Unity Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. Its initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.